New triple inhaler aims to tame tough asthma

NCT ID NCT02676076

Completed Disease control Sponsor: Chiesi Farmaceutici S.p.A. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new inhaler that combines three medicines (beclometasone, formoterol, and glycopyrronium) against a standard two-medicine inhaler in over 1,100 adults with asthma that was not well controlled. The goal was to see if the triple combination improves lung function and reduces asthma attacks over 52 weeks. The trial has been completed, and results are being analyzed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Triple-combination inhaler (beclometasone, formoterol, glycopyrronium)
What this could lead to: If successful, this triple inhaler could offer better lung function and fewer asthma attacks for people whose asthma is not controlled with standard two-drug inhalers.
What could go wrong: This is a completed Phase 3 trial, so results are available, but the benefit over existing treatments may be modest. Side effects from the extra drug are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Locations

Chiesi Clinical Trial Site 276814

Rostock, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.